News | September 10, 2024
Briefs: Wanbury and Bafna Pharmaceuticals
Wanbury receives CEP approval from EDQM for launch of Dextromethorphan API
Wanbury receives CEP approval from EDQM for launch of Dextromethorphan API
The collaborations will help curate industry focused courses such as Advanced Certification courses for healthcare professionals in Healthcare Marketing, Healthcare Technology and Specialized Clinical Fellowship Level programs with university accreditation
The study observed 2,648 girls, of which 2,300 completed the standard 45-day programme
The recent inspection covered both cGMP and PAI processes
The patient has been isolated in a designated hospital and is currently stable
Ami informs that PMDA Japan has issued Inspection Result Report declaring the Sachin facility as a Good Manufacturing Practices (GMP) compliant.
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
The BPaLM regimen, which consists four-drug combination – Bedaquiline, Pretomanid, Linezolid and Moxifloxacin, has been proven to be safe, more effective and a quicker treatment option than the previous MDR-TB treatment procedure
Coal India has committed to providing upto Rs. 3 crore to treat thalassaemia and aplastic anaemia patients for a period of 3 years
Subscribe To Our Newsletter & Stay Updated
